The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.
本发明涉及公式(I)的新化合物,其制备方法以及包含这些化合物的组合物。
METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt
申请人:Janssen Pharmaceutica NV
公开号:US20150105366A1
公开(公告)日:2015-04-16
The present invention comprises compounds of Formula I.
wherein:
R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
, and R
9
are defined in the specification.
The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim
1.
[EN] METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T<br/>[FR] MODULATEURS QUINOLINYLE À LIAISON MÉTHYLÈNE DE ROR-GAMMA-T
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2015057205A1
公开(公告)日:2015-04-23
The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
Two series of potential and selective GlyT1 inhibitors were discovered by bioisosteric replacement.23qwas effective on chronic PCP-treated schizophrenia-like behavioral models.
Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.